Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a recognized risk factor for cardiovascular (CV) disease (CVD).1 In a large, prospective, cohort study of individuals ≥30 years of age, 18% of patients with diabetes developed incident CVD over 5.5 years of follow-up.2 Diabetes in itself increases mortality risk, but the mortality rate nearly doubles in combination with manifestations of CVD [e.g. myocardial infarction (MI) or stroke], translating into an estimated reduction in life expectancy of 12 years.3 Despite this alarming risk, 30–50% of patients with diabetes do not meet guideline-recommended treatment goals for managing CV risk.4 , 5 Only 14% of NHANES (National Health and Nutrition Examination Survey) and BRFSS (Behavioral Risk Factor Surveillance System Survey) participants with diabetes achieved HbA1c, blood pressure, LDL-cholesterol, and non-smoking goals.4 Accordingly, providing optimal cardioprotective treatment strategies remains a major unmet need in this population. Addressing this treatment gap is imperative because of the burdensome prevalence of T2DM, which impacts an estimated 58 million people in Europe, 46 million in the United States, and it is expected to reach 629 million globally by 2045.6 Among glucose-lowering therapies, the sodium-glucose cotransporter-2 (SGLT-2) inhibitors empagliflozin and canagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide reduced the risk of a primary composite outcome of CV death, MI, and stroke when added to standard of care in patients with T2DM who already had or were at risk for CVD (Supplementary material online,Table S1). More than 20 prospective completed or ongoing CV outcome trials (CVOTs) involving approximately 190 000 participants7 were initiated to fulfil the regulatory requirements for clinical investigation of new drugs for diabetes mellitus issued in 2008 by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).8 , 9 The requirements were developed to address concerns surrounding the CV safety of some oral glucose-lowering drugs. These studies ruled out an excess risk of major adverse CV events for saxagliptin, alogliptin, sitagliptin, lixisenatide, and exenatide.10 In addition to the demonstration of CV safety, empagliflozin, canagliflozin, liraglutide, and semaglutide also improved CV outcomes.11–14 This evidence has been incorporated in the labels for empagliflozin, liraglutide, and semaglutide for patients with T2DM and established CVD,15 , 16 and prompt integration into management pathways for such patients has been suggested.17 Several large CVOTs are ongoing with other members of the SGLT-2 inhibitor and GLP-1 receptor agonist classes as well as other glucose lowering therapies. These studies will provide further evidence concerning CV safety and efficacy, and they will also contribute data in broader (i.e. lower risk) patient populations with T2DM. In addition, real world data from large international pharmacoepidemiology cohort studies have shown an association between the new initiation of SGLT-2 inhibitors and a lower risk for major CV outcomes when compared with other glucose lowering drugs.18 , 19 The data from the reported CVOTs have to different degrees been integrated into both diabetes and cardiology guidelines in several countries (Supplementary material online,Table S2). Despite these recommendations, adoption of these cardioprotective therapies in clinical practice remains relatively low.20 , 21 The Cardiovascular Round Table (CRT) of the European Society of Cardiology (ESC) is a strategic forum for high-level dialogue that brings together ESC leadership, academia, regulatory agencies, and industry to facilitate collaboration with a goal of improving CV health in Europe. The ESC CRT convened a workshop in February 2018 to discuss how: best to empower clinicians (i.e. general practitioners/primary care physicians, endocrinologists, and cardiologists) to integrate recent evidence-based glucose-lowering therapies into clinical practice; ESC can promote evolution in guidelines to assist clinicians with the practical implementation of evidence-based therapies; cardiology, endocrinology, and primary care disciplines can collaborate to improve the management and care of patients with T2DM and CVD; and to design future clinical trials of glucose-lowering drugs based on accumulating knowledge. This manuscript summarizes the key outputs from the workshop and describes concepts around collaborative steps to improve implementation of therapy that combines glucose control with CV benefit in patients with T2DM and established CVD or at high CV risk. The completed randomized trials that have demonstrated a beneficial effect of glucose-lowering drugs on CV outcomes are shown in Supplementary material online, Table S1. In the EMPA-REG OUTCOME trial, empagliflozin significantly reduced the primary composite outcome of CV death, non-fatal MI, or non-fatal stroke compared w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citationLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Cited by
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.046 · Cited by 106
Ferrannini, G., De Bacquer, D., De Backer, G., Kotseva, K., Mellbin, L., Wood, D., Rydén, L., collaborators, E. V., Gale, C. P., Beleslin, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2165 · Cited by 75
Self-citationWang, T., Kroeger, C. M., Cassidy, S., Mitra, S., Ribeiro, R. V., Jose, S., Masedunskas, A., Senior, A. M., & Fontana, L. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.25658 · Cited by 60
Yang, R., Xu, H., Pedersen, N. L., Li, X., Yu, J., Bao, C., Qi, X., & Xu, W. (2021) · Diabetologia · doi:10.1007/s00125-020-05324-z · Cited by 28
Giugliano, D., Ceriello, A., De Nicola, L., Perrone‐Filardi, P., Cosentino, F., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13881 · Cited by 22
Self-citation
Metadata
- Authors
- Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., Plutzky, J., Rydén, L., Scheen, A., Standl, E., Tuomilehto, J., & Zannad, F.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-11-16
- Volume
- 40
- Issue
- 34
- Pages
- 2907-2919
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2904596955
- Cited by
- 44
- References
- 21
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. https://app.cochat.ai/papers/10.1093/eurheartj/ehy677
- The paper
- Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., Plutzky, J., Rydén, L., Scheen, A., Standl, E., Tuomilehto, J., & Zannad, F. (2019). Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.